Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal

Jane E Rogers; Ninoska N Silva; Cathy Eng

doi:10.3978/j.issn.2078-6891.2015.035

Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal

J Gastrointest Oncol. 2015 Oct;6(5):E82-5. doi: 10.3978/j.issn.2078-6891.2015.035.

Authors

Jane E Rogers¹, Ninoska N Silva¹, Cathy Eng¹

Affiliation

¹ 1 Pharmacy Clinical Programs, 2 Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, USA.

Abstract

Metastatic squamous cell carcinoma (SCC) of the anal canal is rare with limited data regarding treatment. Epidermal growth factor receptor (EGFR) expression has been observed in SCC of the anal canal and Kristen rat sarcoma vial oncogene (KRAS) mutations are rare. EGFR monoclonal antibodies, cetuximab and panitumumab, represent a potential option in this patient population. We report a metastatic SCC of the anal canal patient treated with cetuximab in combination with cisplatin plus 5-Fluorouracil (5-FU) that had a dramatic response.

Keywords: Cetuximab; anal cancer; epidermal growth factor receptor (EGFR) inhibitors.